-
Posted by
Two Blokes May 27, 2025 -
Filed in
Stock
-
6 views
Toronto, Ontario--(Newsfile Corp. - May 27, 2025) - Awakn Life Sciences Corp. (CSE: AWKN) (OTC Pink: AWKNF) (FSE: 954) ("Awakn" or the "Company"), is pleased to announce, further to its press releases dated February 27, 2025, April 11, 2025 and April 23, 2025, that Solvonis Therapeutics plc (LSE: SVNS) ("Solvonis") has acquired all of the outstanding common shares in the capital of the Company (the "Common Shares"), all outstanding restricted share units (the "RSUs") in the capital of the Company, and all outstanding deferred share units (the "DSUs") in the capital of the Company (the "Transaction"), pursuant to an arrangement (the "Arrangement") under Division 5 of Part 9 of the Business Corporations Act (British Columbia) carried out pursuant to an arrangement agreement dated February 22, 2025 between the Company and Solvonis (the "Arrangement Agreement"). Pursuant to the terms and conditions of the Arrangement Agreement, all holders of outstanding Common Shares will receive 46.67 ordinary shares in the capital of Solvonis (each, a "Solvonis Share") for each one (1) Common Share held.
